Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease

Canadian Respiratory Journal

Volumn 8, Issue 1, 2001, Pages 27-33

  Collet, J P ^a   Ducruet, T ^a   Haider, S ^a   Shapiro, S ^a   Robinson, A ^a   Renzi, P M ^a   Contandriopoulos, A P ^a   Ernst, P ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Acute exacerbation; Chronic obstructive pulmonary disease; Cost effectiveness; Cost benefit analysis; Direct costs; Immunostimulant; Indirect costs; OM 85 BV

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM LYSATE; BRONCHODILATING AGENT; CORTICOSTEROID; IMMUNOSTIMULATING AGENT; OXYGEN; PLACEBO;

ADULT; AGED; ARTICLE; BACTERIUM; CANADA; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035103801     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/508015     Document Type: Article

References (18)

1. Chronic obstructive diseases of the lung
2. Quality of life in patients with chronic airflow limitation
3. Trends in COPD morbidity and mortality in the United States
4. Trends in COPD morbidity and mortality in Tecumseh, Michigan
5. Trends in the epidemiology of COPD in Canada, 1980 to 1995
6. Incidence, prevalence and mortality: Intra- and intercountry differences
7. Chronic airways disease in the United States. Trends and determinants
8. Chronic obstructive pulmonary disease; Socioemotional adjustment and life quality
9. Quality of life and its predictors in patients with mild hypoxemia and chronic obstructive pulmonary disease
10. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease
11. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis
12. Preventive treatment of chronic bronchitis: A cost-effectiveness analysis for an immunoactive bacterial extract in Switzerland
13. Sick population - Treated population: The need for a better definition
14. OM-85 BV for COPD
15. Dyspnoea, disability, and distance walked: Comparison of estimates of exercise performance in respiratory disease